QQQ $ 422.96 $ 1.44 (0.34 %)
DIA $ 384.57 $ -0.58 (-0.15 %)
SPY $ 502.89 $ -0.24 (-0.05 %)
TLT $ 88.37 $ -0.63 (-0.71 %)
GLD $ 214.61 $ -0.40 (-0.19 %)
$ 0.01284
-- x --
-- x --
-- - --
$ 0.01 - $ 3.75
1,921,977
na
12.64M
$ 1.22
$ 0.25
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-27-2024 12-31-2023 10-K
2 11-14-2023 09-30-2023 10-Q
3 08-14-2023 06-30-2023 10-Q
4 06-16-2023 03-31-2023 10-Q
5 04-27-2023 12-31-2022 10-K
6 01-06-2023 09-30-2022 10-Q
7 08-12-2022 06-30-2022 10-Q
8 05-10-2022 03-31-2022 10-Q
9 03-10-2022 12-31-2021 10-K
10 11-15-2021 09-30-2021 10-Q
11 08-11-2021 06-30-2021 10-Q
12 05-06-2021 03-31-2021 10-Q
13 03-04-2021 12-31-2020 10-K
14 11-09-2020 09-30-2020 10-Q
15 08-04-2020 06-30-2020 10-Q
16 05-06-2020 03-31-2020 10-Q
17 03-12-2020 12-31-2019 10-K
18 11-07-2019 09-30-2019 10-Q
19 08-06-2019 06-30-2019 10-Q
20 05-07-2019 03-31-2019 10-Q
21 03-01-2019 12-31-2018 10-K
22 11-07-2018 09-30-2018 10-Q
23 08-02-2018 06-30-2018 10-Q
24 05-14-2018 03-31-2018 10-Q
25 02-26-2018 12-31-2017 10-K
26 11-08-2017 09-30-2017 10-Q
27 08-10-2017 06-30-2017 10-Q
28 05-11-2017 03-31-2017 10-Q
29 03-23-2017 12-31-2016 10-K
30 11-10-2016 09-30-2016 10-Q
31 08-11-2016 06-30-2016 10-Q
32 05-12-2016 03-31-2016 10-Q
33 03-29-2016 12-31-2015 10-K
34 11-12-2015 09-30-2015 10-Q
35 08-13-2015 06-30-2015 10-Q
36 05-14-2015 03-31-2015 10-Q
37 03-26-2015 12-31-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

https://www.washingtonpost.com/world/2024/03/04/france-abortion-constitution/

 laidlaw--co-downgrades-evofem-biosciences-to-hold

Laidlaw & Co. analyst Yale Jen downgrades Evofem Biosciences (OTC:EVFM) from Buy to Hold.

 why-is-life-sciences-focused-aditxt-stock-trading-higher-today

Aditxt Inc (NASDAQ: ADTX) has agreed to acquire Evofem Biosciences Inc (OTC: EVFM) in consideration of the issuance of a combin...

Core News & Articles

Evofem posted $13.4 million in net sales of Phexxifor the first nine months of 2023;Aditxt looks to accelerate Evofem into the ...

 evofem-biosciences-announces-padagis-will-not-seek-fda-approval-to-market-a-generic-version-of-phexxi-until-evofems-phexxi-patents-expire

-- Padagis Determined They Will Not Challenge the Phexxi Patents --  -- Evofem Has Phexxi Patent Protection Through 2033 -- 

 evofem-biosciences-plans-1-for-125-reverse-stock-split

On Thursday May 18, 2023, the Company's common stock will open for trading under a new CUSIP (30048L302) on the OTC Venture...

Core News & Articles

-Reuters

Core News & Articles

Evofem Biosciences, Inc. (OTCQB:EVFM) today announced that Phexxi® (lactic acid, citric acid, potassium bitartrate) has been ad...

Core News & Articles

- Reuters

 benzingas-top-ratings-upgrades-downgrades-for-october-13-2022

Upgrades

 stifel-downgrades-evofem-biosciences-to-hold-lowers-price-target-to-05

Stifel analyst Annabel Samimy downgrades Evofem Biosciences (OTC:EVFM) from Buy to Hold and lowers the price target from $3 ...

 why-evofem-biosciences-shares-are-plunging-today

Evofem Biosciences Inc's (OTC: EVFM) recently completed the Phase 3 EVOGUARD trial evaluating Phexxi vaginal gel (EVO100)...

 evofem-announces-issuance-of-us-patent-covering-phexxi-composition-of-matter-newly-issued-patent-expected-to-provide-protection-for-phexxi-into-at-least-2033

-- Issuance of U.S. Patent No. 11,439,610 Further Strengthens Evofem's Intellectual Patent Portfolio -- -- Newly Issued Pa...

Core News & Articles

https://twitter.com/ZekeJMiller/status/1570831511469060096

 4-analysts-have-this-to-say-about-evofem-biosciences

  Over the past 3 months, 4 analysts have published their opinion on Evofem Biosciences (OTC:EVFM) stock. These analysts are t...

 hc-wainwright--co-maintains-buy-on-evofem-biosciences-raises-price-target-to-4

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Evofem Biosciences (OTC:EVFM) with a Buy and raises the price t...

 why-invitae-climbed-around-279-here-are-98-biggest-movers-from-yesterday

Gainers Invitae Corporation (NYSE: NVTA) surged 278.5% to close at $8.63 after the company reported better-than-expected Q2 ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION